^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/16/2022
    Excerpt:
    Non-Small Cell Lung Cancer: Adjuvant Systemic Therapy…Nivolumab 360 mg and platinum-doublet chemotherapy every 3 weeks for 3 cycles…Platinum-doublet chemotherapy options include: Cisplatin…gemcitabine…(squamous histology)
    Secondary therapy:
    cisplatin + gemcitabine
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy

    Published date:
    10/21/2020
    Excerpt:
    Nivolumab is recommended as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults...